Autoimmune blistering dermatoses as systemic diseases

Clinics in Dermatology

Volumn 32, Issue 3, 2014, Pages 364-375

  Vassileva, Snejina ^a   Drenovska, Kossara ^a   Manuelyan, Karen ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; CHOLINERGIC RECEPTOR; DESMOGLEIN; DESMOGLEIN 1; DESMOGLEIN 2; DESMOGLEIN 3; DESMOGLEIN 4; DESMOPLAKIN; DESMOPLAKIN I; DESMOPLAKIN II; ENVOPLAKIN; GELATINASE A; IMMUNOGLOBULIN A; KALININ; LAMININ GAMMA1; PERIPLAKIN; PLAKOGLOBIN; UNCLASSIFIED DRUG; AUTOANTIBODY; COL4A5 PROTEIN, HUMAN; COLLAGEN TYPE 4; LAMININ;

ADENOCARCINOMA; AUTOIMMUNE BLISTERING DERMATOSES; AUTOIMMUNE DISEASE; BULLOUS PEMPHIGOID; CELIAC DISEASE; CROHN DISEASE; DERMATITIS HERPETIFORMIS; DERMOEPIDERMAL JUNCTION; DRUG INDUCED DISEASE; DRUG INDUCED PEMPHIGUS; EPIDERMOLYSIS BULLOSA ACQUISITA; ERYTHEMATOUS PEMPHIGUS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOLOGY; INFLAMMATORY BOWEL DISEASE; KIDNEY DISEASE; LINEAR IGA BULLOUS DERMATOSIS; MICROSCOPY; NOTE; PARANEOPLASTIC PEMPHIGUS; PATHOPHYSIOLOGY; PEMPHIGOID GESTATIONIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VEGETANS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; BULLOUS SKIN DISEASE; COMPLICATION; DIGESTIVE SYSTEM DISEASE; ENDOCRINE DISEASE; IMMUNOLOGY; INFLAMMATION; MENTAL DISEASE; MUCOUS MEMBRANE PEMPHIGOID; NEOPLASM; NEUROLOGIC DISEASE; PARANEOPLASTIC SYNDROME;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; COLLAGEN TYPE IV; DERMATITIS HERPETIFORMIS; DIGESTIVE SYSTEM DISEASES; ENDOCRINE SYSTEM DISEASES; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMANS; INFLAMMATION; KIDNEY DISEASES; LAMININ; LINEAR IGA BULLOUS DERMATOSIS; MENTAL DISORDERS; NEOPLASMS; NERVOUS SYSTEM DISEASES; PARANEOPLASTIC SYNDROMES; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PEMPHIGOID, BULLOUS; PEMPHIGUS; SKIN DISEASES, VESICULOBULLOUS;

EID: 84899107043     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2013.11.003     Document Type: Note

References (93)

1. Fridkis-Hareli M. Immunogenetic mechanisms for the coexistence of organ-specific and systemic autoimmune diseases. J Autoimmune Dis 2008, 5:1-7.
2. Callen J.P. Internal disorders associated with bullous disease of the skin. A critical review. J Am Acad Dermatol 1980, 3:107-119.
3. Kaplan R.P., Callen J.P. Pemphigus associated diseases and induced pemphigus. Clin Dermatol 1983, 1:42-71.
4. Anhalt G.J., Kim S.C., Stanley J.R., et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990, 323:1729-1735.
5. Ljubojevic S., Lipozenčić J. Autoimmune bullous diseases associations. Clin Dermatol 2012, 30:17-33.
6. Brenner S., Tur E., Shapiro J., et al. Pemphigus vulgaris: Environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol 2001, 40:562-569.
7. Nikolskaia O.V., Nousari C.H., Anhalt G.J. Paraneoplastic pemphigus in association with Castleman's disease. Br J Dermatol 2003, 149:1143-1151.
8. Bowen G.M., Peters N.T., Fivenson D.P., et al. Lichenoid dermatitis in paraneoplastic pemphigus: A pathogenic trigger of epitope spreading?. Arch Dermatol 2000, 136:652-656.
9. Lee S.E., Kim S.C. Paraneoplastic pemphigus. Dermatologica Sinica 2010, 28:1-14.
10. Frew J.W., Murrell D.F. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): Clinical presentations and pathogenesis. Dermatol Clin 2011, 29:419-425.
11. Hashimoto T., Amagai M., Watanabe K., et al. Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol 1995, 104:829-834.
12. Camisa C., Helm T.N. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol 1993, 129:883-886.
13. Joly P., Richard C., Gilbert D., et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 2000, 43:619-626.
14. Nguyen V.T., Ndoye A., Bassler K.D., et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: A reappraisal of paraneoplastic pemphigus. Arch Dermatol 2001, 137:193-206.
15. Czernik A., Camilleri M., Pittelkow M.R., et al. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol 2011, 50:905-914.
16. Mimouni D., Anhalt G.J., Lazarova Z., et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 2002, 147:725-732.
17. Kimyai-Asadi A., Jih M.H. Paraneoplastic pemphigus. Int J Dermatol 2001, 40:367-372.
18. Tsankov N., Vassileva S., Kamarashev J., et al. Epidemiology of pemphigus in Sofia, Bulgaria. A 16-year retrospective study (1980-1995). Int J Dermatol 2000, 39:104-108.
19. Martel P., Loiseau P., Joly P., et al. Paraneoplastic pemphigus is associated with the DRB1*03 allele. J Autoimmun 2003, 20:91-95.
20. Duparc A., Boivin S., Gilbert D., Piette F., Delaporte E. Paraneoplastic pemphigus with pemphigus vegetans-like lesions revealing non-Hodgkin lymphoma. Eur J Dermatol 2006, 16:698-699.
21. Zhu X., Zhang B. Paraneoplastic pemphigus. J Dermatol 2007, 34:503-511.
22. Leger S., Picard D., Ingen-Housz-Oro S., et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol 2012, 148:1165-1172.
23. Senear F.E., Usher B. Unusual type of pemphigus combining features of lupus erythematosus. Arch Dermatol 1926, 13:761.
24. Pérez-Pérez M.E., Herrera-Esparza R., Avalos-Díaz E. Autoantibodies in Senear-Usher syndrome: Cross-reactivity or multiple autoimmunity?. Autoimmune Dis 2012, 2012:296214.
25. Maize J.C., Green D., Provost T.T. Pemphigus foliaceus: A case with serologic features of Senear-Usher syndrome and other autoimmune abnormalities. J Am Acad Dermatol 1982, 7:736-741.
26. Steffen C., Thomas D. The men behind the eponym: Francis E. Senear, Barney Usher, and the Senear-Usher syndrome. Am J Dermatopathol 2003, 25:432-436.
27. Abreu-Velez A.M., Hashimoto T., Bollag W.B., et al. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol 2003, 49:599-608.
28. Diaz L.A., Sampaio S.A.P., Rivitti E.A., et al. Endemic pemphigus foliaceus (fogo selvagem). I. Clinical features and immunopathology. J Am Acad Dermatol 1989, 20:657-659.
29. Friedman H., Campbell I., Rocha-Alvarez R., et al. Endemic pemphigus foliaceus (fogo selvagem) in native Americans from Brazil. J Am Acad Dermatol 1995, 32:949-956.
30. Paradisi A., Sampogna F., Di Pietro C., et al. Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools. J Am Acad Dermatol 2009, 60:261-269.
31. Ghodsi S.Z., Chams-Davatchi C., Daneshpazhooh M., Valikhani M., Esmaili N. Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires. J Dermatol 2012, 39:141-144.
32. Sebaratnam D.F., McMillan J.R., Werth V.P., et al. Quality of life in patients with bullous dermatoses. Clin Dermatol 2012, 30:103-107.
33. Roussel A., Benichou J., Randriamanantany Z.A., et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011, 147:293-298.
34. Foureur N., Descamps V., Lebrun-Vignes B., et al. Bullous pemphigoid in a leg affected with hemiparesia: A possible relation of neurological diseases with bullous pemphigoid?. Eur J Dermatol 2001, 11:230-233.
35. Langan S.M., Groves R.W., West J. The relationship between neurological disease and bullous pemphigoid: A population-based case-control study. J Invest Dermatol 2011, 131:631-636.
36. Li J., Zuo Y.G., Zheng H.Y., et al. Association between bullous pemphigoid and internal diseases. J Dtsch Dermatol Ges 2013, 11:263-264.
37. Bastuji-Garin S., Joly P., Lemordant P., et al. Risk factors for bullous pemphigoid in the elderly: A prospective case-control study. J Invest Dermatol 2011, 131:637-643.
38. Taghipour K., Chi C.C., Vincent A., et al. The association of bullous pemphigoid with cerebrovascular disease and dementia: A case-control study. Arch Dermatol 2010, 146:1251-1254.
39. Leung C.L., Zheng M., Prater S.M., et al. The BPAG1 locus: Alternative splicing produces multiple isoforms with distinct cytoskeletal linker domains, including predominant isoforms in neurons and muscles. J Cell Biol 2001, 154:691-697.
40. Chen J., Li L., Chen J., et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology 2011, 57:211-216.
41. Swerlick R.A., Korman N.J. Bullous pemphigoid: What is the prognosis?. J Invest Dermatol 2004, 122:xvii-xviii.
42. Venning V.A., Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 1992, 26:585-589.
43. Rzany B., Partscht K., Jung M., et al. Risk factors for lethal outcome in patients with bullous pemphigoid: Low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002, 138:903-908.
44. Joly P., Roujeau J.C., Benichou J., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346:321-327.
45. Gudi V.S., White M.I., Cruickshank N., et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol 2005, 153:424-427.
46. Tanaka M., Hashimoto T., Dykes P.J., et al. Clinical manifestation in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles. Clin Exp Dermatol 1996, 21:23-27.
47. Bernard P., Bedane C., Bonnetblanc J.M. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: A cohort analysis of 94 elderly patients. Br J Dermatol 1997, 136:694-697.
48. Di Zenzo G., Thoma-Uszynski S., Calabresi V., et al. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol 2011, 131:2271-2280.
49. Mignogna M.D., Fortuna G., Leuci S., et al. Lichen planus pemphigoides, a possible example of epitope spreading. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010, 109:837-843.
50. Vassileva S., Mateev G., Balabanova M., et al. Burn-induced bullous pemphigoid. J Am Acad Dermatol 1994, 30:1027-1028.
51. Vassileva S. Drug-induced pemphigoid: Bullous and cicatricial. Clin Dermatol 1998, 16:379-389.
52. Egan C.A., Lazarova Z., Darling T.N., et al. Anti-epiligrin cicatricial pemphigoid: Clinical findings, immunopathogenesis, and significant associations. Medicine (Baltimore) 2003, 82:177-186.
53. Egan C.A., Lazarova Z., Darling T.N., et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001, 357:1850-1851.
54. Young A.L., Bailey E.E., Colaço S.M., et al. Anti-laminin-332 mucous membrane pemphigoid associated with recurrent metastatic prostate carcinoma: Hypothesis for a paraneoplastic phenomenon. Eur J Dermatol 2011, 21:401-404.
55. Setterfield J., Shirlaw P.J., Lazarova Z., et al. Paraneoplastic cicatricial pemphigoid. Br J Dermatol 1999, 141:127-131.
56. Mitsuya J., Hara H., Ito K., et al. Metastatic ovarian carcinoma-associated subepidermal blistering disease with autoantibodies to both the p200 dermal antigen and the gamma 2 subunit of laminin 5 showing unusual clinical features. Br J Dermatol 2008, 158:1354-1357.
57. Zillikens D. Autoimmune bullous diseases. Braun-Falco's Dermatology 2009, 656-657. Springer, Heidelberg. 3rd ed. W.H.C. Burgdorf, G. Plewig, H.H. Wolff, M. Landthaler (Eds.).
58. Chi C.C., Wang S.H., Charles-Holmes R., et al. Pemphigoid gestationis: Early onset and blister formation are associated with adverse pregnancy outcomes. Br J Dermatol 2009, 160:1222-1228.
59. Zillikens D., Kawahara Y., Ishiko A., et al. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 1996, 106:1333-1338.
60. Dainichi T., Koga H., Tsuji T., et al. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid. J Dermatol 2010, 37:231-238.
61. Schmidt E., Zillikens D. Pemphigoid diseases. Lancet 2013, 381:320-332.
62. Ghohestani R.F., Hudson B.G., Claudy A., et al. The alpha 5 chain of type IV collagen is the target of IgG autoantibodies in a novel autoimmune disease with subepidermal blisters and renal insufficiency. J Biol Chem 2000, 275:16002-16006.
63. Ghohestani R.F., Rotunda S.L., Hudson B., et al. Crescentic glomerulonephritis and subepidermal blisters with autoantibodies to alpha5 and alpha6 chains of type IV collagen. Lab Invest 2003, 83:605-611.
64. Allen J., Wojnarowska F. Linear IgA disease: The IgA and IgG response to dermal antigens demonstrates a chiefly IgA response to LAD285 and a dermal 180-kDa protein. Br J Dermatol 2003, 149:1055-1058.
65. Wojnarowska F., Marsden R.A., Bhogal B.S., et al. Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol 1988, 19:792-805.
66. Collier M., Kelly S.E., Wojnarowska F. Linear IgA disease and pregnancy. J Am Acad Dermatol 1994, 30:407-411.
67. Kelly S.E., Frith P.A., Millard P.R., et al. A clinicopathological study of mucosal involvement in linear IgA disease. Br J Dermatol 1988, 119:161-170.
68. Shipman A.R., Reddy H., Wojnarowska F. Association between the subepidermal autoimmune blistering diseases linear IgA disease and the pemphigoid group and inflammatory bowel disease: Two case reports and literature review. Clin Exp Dermatol 2012, 37:461-468.
69. Oranje A.P., Vuzevski V.D., Bouquet J., et al. Linear IgA disease and chronic active hepatitis-a coincidence or not?. Acta Derm Venereol 1985, 65:440-442.
70. Kapur A., Isaacs P.E., Kelsey P.R. Linear IgA dermatosis, coeliac disease, and extraintestinal B cell lymphoma. Gut 1995, 37:731-733.
71. Girao L., Fiadeiro T., Rodrigues J.C. Burn-induced linear IgA dermatosis. J Eur Acad Dermatol Venereol 2000, 14:507-510.
72. Nicolas M.E.O., Krause P.K., Gibson L.E., et al. Dermatitis herpetiformis. Int J Dermatol 2003, 42:588-600.
73. Alonso-Llamazares J., Gibson L.E., Rogers R.S. Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience. Int J Dermatol 2007, 46:910-919.
74. Korponay-Szabó I.R., Halttunen T., Szalai Z., et al. In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 2004, 53:641-648.
75. Hadjivassiliou M., Mäki M., Sanders D.S., et al. Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. Neurology 2006, 66:373-377.
76. Helsing P., Frøen H. Dermatitis herpetiformis presenting as ataxia in a child. Acta Derm Venereol 2007, 87:163-165.
77. Sardy M., Karpati S., Peterfy F., et al. Comparison of a tissue transglutaminase ELISA with the endomysium antibody test in the diagnosis of gluten-sensitive enteropathy. Z Gastroenterol 2000, 38:357-364.
78. Lara-Corrales I., Pope E. Autoimmune blistering diseases in children. Semin Cutan Med Surg 2010, 29:85-91.
79. Sigurgeirsson B., Agnarsson B.A., Lindelof B. Risk of lymphoma in patients with dermatitis herpetiformis. Br Med J 1994, 308:13-15.
80. Reunala T., Collin P. Diseases associated with dermatitis herpetiformis. Br J Dermatol 1997, 136:315-318.
81. Finelli P.F., McEntee W.J., Ambler M., et al. Adult celiac disease presenting as cerebellar syndrome. Neurology 1980, 30:245-249.
82. Wills A.J., Turner B., Lock R.J., et al. Dermatitis herpetiformis and neurological dysfunction. J Neurol Neurosurg Psychiatry 2002, 72:259-261.
83. Reunala T. Dermatitis herpetiformis: Coeliac disease of the skin. Ann Med 1998, 30:416-418.
84. Chen M., O'Toole E.A., Sanghavi J., et al. The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with Crohn's disease have autoantibodies to type VII collagen. J Invest Dermatol 2002, 118:1059-1064.
85. Reddy H., Shipman A.R., Wojnarowska F. Epidermolysis bullosa acquisita and inflammatory bowel disease: A review of the literature. Clin Exp Dermatol 2013, 38:225-229.
86. Hundorfean G., Neurath M.F., Sitaru C. Autoimmunity against type VII collagen in inflammatory bowel disease. J Cell Mol Med 2010, 14:2393-2403.
87. Kim G., Chen M., Hallel-Halevy D., et al. Autoimmune bullous skin disorders. Autoimmune Diseases of the Skin. Pathogenesis, Diagnosis, Management. New York; Springer 2011, 113-136.
88. Camisa C., Sharma H.M. Vesiculobullous systemic lupus erythematosus. J Am Acad Dermatol 1983, 9:924-933.
89. Sebaratnam D.F., Murrell D.F. Bullous systemic lupus erythematosus. Dermatol Clin 2011, 29:649-653.
90. Vassileva S. Bullous systemic lupus erythematosus. Clin Dermatol 2004, 22:129-138.
91. Patricio P., Ferreira C., Gomes M.M., et al. Autoimmune bullous dermatoses: A review. Ann N Y Acad Sci 2009, 1173:203-210.
92. Gammon W.R., Heise E.R., Burke W.A., et al. Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen. Evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol 1988, 91:228-232.
93. Vassileva S. Lupus erythematosus. Diagnostic Immunohistochemistry of the Skin 1998, 144-156. Chapman & Hall, London. J. Kanitakis, S. Vassileva, D. Woodley (Eds.).